Handelsbanken Fonder AB Sells 1,900 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Handelsbanken Fonder AB cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 14.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,100 shares of the biotechnology company’s stock after selling 1,900 shares during the period. Handelsbanken Fonder AB’s holdings in United Therapeutics were worth $3,917,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after acquiring an additional 45,566 shares during the last quarter. FMR LLC raised its stake in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of United Therapeutics by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 12.3% in the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after acquiring an additional 50,409 shares during the last quarter. Finally, Assetmark Inc. raised its stake in shares of United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after buying an additional 152,249 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Down 1.7 %

Shares of UTHR stock opened at $361.10 on Monday. The company’s fifty day simple moving average is $362.68 and its 200-day simple moving average is $360.72. The firm has a market cap of $16.12 billion, a PE ratio of 15.86, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $214.75 and a 12 month high of $417.82.

Insiders Place Their Bets

In related news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 114,164 shares of company stock valued at $41,671,293. 11.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.